Context: Little is known about the relationship between TSH-receptor antibody (TSHR-Ab) and the severity and course of ophthalmopathy.
that measurement of TSH receptor antibody (TSHR-Ab) may help predict the evolution of GO severity. A high TSHRAb soon after the onset of GO and that remains persistently high, would predict the severity of the course of GO. Thus, determination of the level of TSHR-Ab could influence the management of the disease. Suprisingly, severity of GO was determined later, after a follow-up period of 11-14 months, after various antithyroid treatments and also after many patients had been treated with glucocorticoids, irradiation or both. Half of the patients were in the grey zone, probably because of the non-uniform classification of patients, heterogeneity of the group, different antithyroid treatments used, modification of the degree of GO severity and activity of the disease during follow-up. Other prospective follow-up studies are needed to confirm the present hypothesis. I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. If T 4 -suppressed Tg was 0.1-0.5 or 0.6-2.0 ng/ml, rhTSH Tg was above 2 ng/ml in 24.2 and 82.4%, respectively.
Conclusions:
Patients with differentiated thyroid carcinoma and a T 4 -suppressed serum Tg below 0.1 ng/ml rarely have a rhTSH-stimulated Tg above 2 ng/ml, and none of these patients had 131 I or 123 I imaging after rhTSH stimulation suggestive of local recurrence or distant metastasis. The authors recommend monitoring such patients with a T 4 -suppressed Tg level and periodic neck ultrasonography. An increase in T 4 -suppressed serum Tg to a detectable level or the appearance of abnormal lymph nodes by physical or ultrasound examination should prompt further investigation.
COMMENT
The development of Tg assays and recombinant human TSH (rhTSH) have provided the means for clinicians to detect residual (or recurrent) thyroid cancer. The combined use of serum Tg and whole body scan (WBS) after stimulation with rhTSH is particularly effective in identifying small residual foci of thyroid tissue (either normal glandular remnants and/or cancer). This study is based on the experience of the Mayo Clinic group, using a serum Tg assay with a clinical detection limit of 0.1 ng/ml, i.e. a sensitivity considerably lower than the 0.5 to 1.0 ng/ml levels reported in other studies. The data showed that in 80 patients with T 4 -suppressed (i.e. under treatment) Tg below 0.1 ng/ml, Tg remained undetectable in 47/80 patients (59%) after rhTSH; furthermore in 78/80 patients (97.5%), stimulated Tg was below 2 ng/ml. Only one of 80 patients had treatment for recurrent disease. Thus, a rare patient may have detectable disease despite a very low serum Tg (and in their case negative imaging by scintigraphy), emphasizing the importance of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer (DTC). What is proposed in this report is that by using a sensitive Tg-immunoassay with a very low cut-off, it is possible to follow patients with DTC and a T 4 -suppressed Tg below 0.1 ng/ml without the need to perform rhTSH stimulation. If T 4 -suppressed Tg levels are detectable, the recent guidelines of ATA/ETA should be followed because 24-82% of such patients have a rhTSH-stimulated Tg above 2 ng/ml, hence prompting additional workup to identify residual cancer. Two last comments: a) the testing laboratory has to ensure consistent assay performance over time; and b) patients should always be tested with the same highly sensitive Tg assay. Finally, additional studies using Tg assays with improved sensitivity and longer follow-up are needed before deciding universally that monitoring such patients with a low risk cancer grade could be recommended by carrying out a yearly T 4 -suppressed Tg measurement and periodic neck ultrasound imaging, but without rhTSH stimulation. 
See Figure below
Upper panel: the results from Mayo Clinic (Florida): only 1 of 47 patients with a baseline Tg ('pre') below 0.1 ng/ml had a rhTSH-stimulated Tg ('post') above 2 ng/ml.
Lower panel: the results from Mayo Clinic (Rochester): in 15/33 patients (45.4%), baseline Tg ('pre') below 0.1 ng/ml remained undetectable after rhTSH ('post') and in 17/33 patients (51.3%) stimulated Tg levels were less than 2 ng/ml. Objective: This study aimed to investigate the ontogeny of thyroglobulin (Tg), thyroid peroxidase (TPO), sodium/iodide symporter (NIS), pendrin (PDS), dual oxidase 2 (DUOX2), thyroid stimulating hormone receptor (TSHR), and thyroid transcription factor 1 (TITF1), forkhead box E1 (FOXE1) and paired box gene 8 (PAX8) in the developing human fetus.
Design: Thyroid tissues from 45 human embryos and fetuses (7-33 GW) were analysed by quantitative PCR to monitor mRNA expression for each gene and by immuno-histochemistry to determine the cellular distribution of TITF1, TSHR, Tg, TPO, NIS, and the onset of T 4 production. A broken line regression model was fitted for each gene to compare the log-linear increase in expression before and after the onset of T 4 production.
Results: TITF1, FOXE1, PAX8, TSHR, and DUOX2 were stably expressed from 7 to 33 GW. Tg, TPO, and PDS gene expressions were detectable as early as 7 GW and were correlated with gestational age (P < 0.01). The slope of the regression line was significantly different before and after the onset of T 4 synthesis at 11 GW (P < 0.01). NIS expression appeared last and showed the highest fit by the broken line regression model of all genes (correlation age: P < 0.0001; broken line regression: P < 0.0001). Immuno-histochemical studies detected TITF1, TSHR, and Tg in unpolarized thyrocytes before follicle formation. T 4 and NIS labelling were only found in developing follicles from 11 GW on.
Conclusion:
These results imply a key role of NIS for the onset of human thyroid function.
COMMENT
The developing human thyroid gland undergoes a series of complex changes during embryogenesis in order to become functional. Morphogenesis is completed when the thyroid reaches its definitive pretracheal position -at 7 weeks gestation -but, at this early stage, the gland is mainly composed of undifferentiated thyrocyte precursors.
Three morphological differentiation stages can be distinguished: precolloid, beginning colloid, and follicular growth stage. Differentiation includes several changes: the polarization of thyrocyte precursors (with basal & apical poles), followed by follicle formation (allowing colloid to be accumulated), and the expression of thyroid-specific functional genes, such as thyroglobulin 'Tg' (the matrix on which thyroid hormone can be produced), thyroperoxidase 'TPO' (the enzyme needed to catalyse iodine incorporation onto the Tg matrix), thyroid-stimulating hormone receptor 'TSHR' (main regulator -at the basolateral thyrocyte membrane level -of thyroid growth & function, via hypothalamic-pituitary control), and sodium/iodide symporter 'NIS' (the pump needed to trap iodide from the circulation).
The present study is fascinating as it is the first attempt to investigate the sequence of this molecular program of human thyroid differentiation.
The results show essentially that a precisely timed expression program exists. DUOX2 expression is stable already at 7 weeks gestation. A second group of genes (Tg, TPO, PDS) are expressed at low levels first, then increase significantly before 11 weeks gestation, and their increased expression is correlated with the onset of thyroid function. NIS is the last gene to appear, and its expression is the most strongly correlated with the rapid onset of thyroid hormone synthesis at 11 weeks gestation. This expression pattern suggests that NIS expression is the rate limiting step for the onset of thyroid function in man. In other words, all parts of the complex puzzle must first be in place for iodide to be actively trapped and organified within an already organized thyroid gland, allowing thyroid hormone to be produced.
It is important to note that this study is purely qualitative, as it does not allow to assess which quantitative fraction of the overall fetal thyroid hormone environment is related to the onset of T 4 synthesis at such early embryonic stage (first trimester of gestation). Therefore, the presence of T 4 in the anatomical structures bathing the developing embryo (amniotic and coelomic fluid) remains presumably mostly due to maternal transfer of thyroid hormone. Even though fetal T 4 synthesis may be starting around 11-12 weeks, it is not until 16-20 weeks gestation that the fetal hormone contribution to this crucial environment may become relevant. In parathyroidectomy, it has been recognized that a shift to a minimally invasive procedure may be accompanied by a possibility of missing thyroid pathology. However, only a few findings concerning preoperative thyroid evaluation have been reported.
Aim:
The authors investigated the prevalence of concomitant thyroid pathology by preoperative neck ultrasonography (US) in patients with primary hyperparathyroidism.
Design: There were 85 patients (66 women; 19 men; mean age 57 years) in the study group. The mean preoperative calcium level was 11.2 mg/dl and the mean intact PTH level was 206 pg/ml. All patients underwent neck US following fine-needle aspiration biopsy (FNAB).
Results:
Of the 85 patients, 21 (24.7%) had thyroid nodules. Among 21 patients with thyroid nodules, 9 (10.6%) had malignant thyroid tumors, while 12 (14.1%) had benign thyroid nodules, including multinodular goiter. Of the 9 patients with malignant thyroid nodules, 4 had papillary carcinomas with lymph node metastases.
Conclusion:
The prevalence of thyroid disease associated with hyperparathyroidism is high, and evaluation of the thyroid pathology by US enables the shift from bilateral neck exploration to the minimally invasive parathyroid surgery.
COMMENT
This article focuses on the surgical shift from open neck exploration for primary hyperparathyroidism (PHPT) due to parathyroid adenoma to minimally invasive procedures and, in turn, the greater possibility of missing associated thyroid pathology. It also focuses on the capacity of detecting such associated thyroid lesions by the use of preoperative neck ultrasonography (US). Thyroid nodules were found in 25% of patients operated for PHPT and, among these, thyroid malignancy was present in 9/21 patients (43%). Of interest, 6/9 thyroid cancers were not palpable (thus corresponding to incidentalomas). Tumor sizes ranged from 5-32 mm among the non palpable tumors, and from 20-80 mm among the palpable tumors. The prevalence of thyroid malignancies in this series was greater than the 2-6% reported in others series from the literature (perhaps because of geographical differences and/or the preoperative use of US and FNAB). The association between TSH and serum lipids in people with no apparent thyroid disease is insufficiently understood. The authors have studied the association between normal thyroid function, defined as TSH within the reference range of a general population, and concentrations of serum lipids.
Design: Cross-sectional, population-based study with 30.656 individuals without known thyroid disease.
Methods:
Using general linear models, the authors calculated mean concentrations of total serum cholesterol, LDL-cholesterol, non-HDL-cholesterol, HDL-cholesterol, and triglycerides across categories of TSH.
Results:
Within the reference range of TSH, there was a linear and significant (P for trend < 0.001) increase in total serum cholesterol, LDL-cholesterol, non-HDL-cholesterol, and triglycerides, and a linear decrease (P for trend < 0.001) in HDL-cholesterol with increasing TSH. Subgroup analyses showed statistically significant associations for all lipids in men above 50 years of age, and for triglycerides in all age groups. For women, associations were statistically significant in all age groups except for HDL-cholesterol below 50 years of age. The associations with triglycerides and HDLcholesterol were stronger among overweight than normal weight individuals.
Conclusion:
Within the range of TSH that is considered clinically normal, the authors found that increasing level of TSH was associated with less favourable lipid concentrations. The association with serum lipids was linear across the entire reference range of TSH.
COMMENT
An important clinical consequence of hypothyroidism is its association with an increased risk of cardiovascular disease, which is thought to be mediated in part by the changes in serum lipids that often accompany hypothyroidism. For instance in subclinical hypothyroidism (SCH), defined as increased serum TSH (usually between 4-10 µU/ml) with normal serum free T 4 levels, the benefit of early treatment with thyroxine has only been clearly demonstrated when serum lipids abnormalities are present. In such patients, studies have shown that thyroxine administration may be beneficial to reduce total serum cholesterol and LDLcholesterol. A meta-analysis (in 1996) concluded that normalization of serum TSH in patients with SCH was associated with a decrease in serum cholesterol by 0.4 mMol/L on average (Tanis et al., Clin Endocrinol., 44:643, 1996) . A more recent meta-analysis also concluded that normalization of serum TSH decreased serum LDL-cholesterol by 0.26 mMol/L (Danese et al., JCEM 85:2993 , 2000 . Reduction in serum total and LDLcholesterol may be larger in individuals with higher cholesterol levels prior to treatment. The observed decrease in LDLcholesterol is estimated to decrease the risk of cardiovascular mortality by 9-31% (Meier et al., JCEM 86:4860, 2001 ). The main finding of present study was to show a consistent, linear, and significant increase in concentrations of total serum cholesterol, LDL-cholesterol, non-HDLcholesterol, and triglycerides, in both men and women, with increasing concentration of serum TSH within the reference range of 0.5-3.5 µU/ml. There was also a consistent reduction in HDL-cholesterol with increasing TSH. In a separate analysis, an additional interesting finding of present study was that, in the context of this population study, the authors had a database concerning 2.007 patients with SCH. When the data from patients with SCH were analysed with those of the normal subjects, there was a continuum for further increases in total serum cholesterol, LDL-cholesterol, non-HDL-cholesterol, and triglycerides, but no clear association with decreased HDL-cholesterol. In conclusion, TSH levels representative of normal thyroid function may have longterm harmful effects on cardiovascular health through the association with serum lipids. However, the strengths of the associations were modest, and their clinical significance remains to be determined in prospective studies of variations of normal thyroid function related to risk of cardiovascular disease. 
SUMMARY
Objective: Standard drug information resources recommend that l-thyroxine be taken half an hour before breakfast on an empty stomach, to prevent interference of its intestinal uptake by food or medication. The authors have observed cases in which TSH levels improved markedly after changing the administration time of l-thyroxine to the late evening. They conducted therefore a pilot-study to investigate whether l-thyroxine administration at bedtime improves TSH and thyroid hormones, and whether the circadian rhythm of TSH remains intact.
Design: Patients were studied on two occasions: on a stable regimen of morning thyroxine administration and two months after switching to night-time thyroxine (l-T4) using the same dose. On each occasion patients were admitted for 24h and serial blood samples were obtained.
Patients and measurements:
Twelve women treated with l-T4 for primary hypothyroidism were investigated. They used no medication known to interfere with l-T4 uptake. Patients were admitted to hospital and blood samples were obtained at hourly intervals for 24k via an indwelling catheter. Following this first hospital admission, all women were then asked to switch the administration time from morning to bedtime or vice-versa. After two months they were readmitted for a 24h period of hourly blood sampling. Blood samples were analysed for serum TSH, free T4 and free T3, total T4 and reverse T3, serum TBG, and total protein and albumin.
Results: A significant difference in TSH and thyroid hormones was found after switching to bedtime administration of l-T4. Comparing bedtime to morning ingestion, the twenty-four hour average serum values showed: -TSH: 5.1 + 0.9 versus 1.2 + 0.3 µU/ml (mean + SD) (P < 0.01); -free T4: 16.7 + 1.0 versus 19.3 + 0.7 pMol/L (mean + SD) (P < 0.01); -total T3: 1.48 + 0.05 versus 1.64 + 0.1 nMol/L (mean + SD) (P < 0.01). There was no significant change in total T4, reverse T3, albumin and TBG levels, nor in the T3/rT3 ratio. The relative amplitude and time of the nocturnal TSH surge remained intact.
Conclusion: L-thyroxine taken at bedtime by patients with primary hypothyroidism is associated with higher thyroid hormone concentrations and lower TSH concentrations compared to the same l-T4 dose taken in the morning. The circadian TSH rhythm stays intact. These findings are best explained by a better gastrointestinal uptake of l-T4 during the night.
COMMENT
This is quite an interesting study with unexpected -and potentially importantfindings. We always tell our patients to take their thyroxine tablet in the morning "as soon as they wake up". We also all see a few patients who, for various reasons, prefer to take their drug in the evening and, as long as they take it two hours (at least) after their last meal, we tell them that it is all right. And indeed, their thyroid function tests are usually OK and indistinguishable from patients who take thyroxine in the morning. Those are the dogmas we have been trained with and, in turn, train our medical students with. For the first time to our knowledge, a well-conducted study shows clear differences between morning and evening thyroxine ingestion, using the same dosage and in the same set of patients. Dogmas are there to be challenged. Is this one more dogma to throw away? The authors speculate that the differences might be attributable to a lesser intestinal absorption of thyroxine in the morning and they provide some arguments in favour of a better degree of intestinal absorption in the evening. Is this convincing and also does it really matter? You will have to decide for yourself but I will certainly switch a few of my patients from Results: Histological diagnosis of malignancy was carried out in 125 of 505 (25%) patients, the follicular variant of papillary carcinoma being the most frequent histotype. Only atypia at cytology and spot micro-calcifications at ultrasound were significantly predictive of malignancy. Male gender, normal thyroid volume, single nodularity, nodule hypoechogenicity, size and blurred margins were associated with malignancy, although not significantly. An arbitrary clinical score allowed the identification of patients with high (41%; 110 patients) and low (16%; 242 patients) risk of malignancy. Combining the clinical score with the presence of atypia at cytology, the authors could identify 30 patients (6%) in whom the risk of malignancy was as high as 63%.
Conclusion:
Twenty-five percent of patients with a cytological result of follicular and Hürthle cell thyroid lesion had a final diagnosis of malignancy. Only atypia at cytology and spot microcalcifications at thyroid ultrasound were significantly associated with malignancy. Other clinical parameters and thyroid ultrasound patterns can be used to set up a clinical score useful for predicting the individual risk of malignancy before surgery.
COMMENT
Thyroid nodules are frequent in the general population and only a minority of these nodules are likely to cause significant clinical problems. The introduction of fineneedle aspiration cytology (FNAC) in the mid-seventies (1975 in the USA, 1979 in Belgium) has allowed to markedly reduce the number of patients submitted to thyroid surgery for benign nodular lesions and increase in turn the prevalence of malignancy in surgical series. However, FNAC has its limitations, especially when the cell pattern shows follicular proliferation. Such pattern can be found in follicular carcinoma and in the follicular variant of papillary carcinoma, but also in hyperplastic nodules within a benign goiter and follicular adenoma. Based solely on cytological criteria, the distinction between benign and malignant follicular neoplasia is not feasible without histology. Similarly, Hürthle cells (oncocytes or oxyphilic cells) can be found in Hürthle cell adenomas and carcinomas and histology is needed for the final diagnosis of an oncocytoma. Such cytological patterns (follicular proliferation and/or oncocytes) are classified among the indeterminate diagnoses or "atypia" in FNAC and, therefore, the objective of present study was to assess whether the finding of atypia at FNAC, associated with specific clinical parameters and echographic patterns could be useful to predict malignancy. The study is also of interest because of the large number of patients included (over 500) from the same institution. Of the 505 patients, 426 had a follicular lesion and 79 a Hürthle cell lesion at FNAC. Among them, 25% had a final diagnosis of thyroid malignancy at histology. Histological diagnosis of malignancy was made in 46/101 nodules (45%) presenting atypia and in 79/404 nodules (20%) without atypia (P<0.001). In follicular nodules, malignancy was found in 40/83 samples with atypia compared with 76/343 without atypia (P<0.001). Clinical parameters were found to be of little help to identify malignancy. With regard to specific echographic parameters, only spot micro-calcifications (P=0.009) and blurred nodular margins (P=0.06) were associated with malignancy. The authors constructed an arbitrary clinical score which allowed the identification of patients with a high (41%) versus a low (16%) risk of malignancy. Combining the clinical score with the presence of atypia at cytology, the authors could identify 30 patients (6%) in whom the risk of malignancy was as high as 63%. Finally even in the subgroup with the lower risk, malignancy was found in 16% of the patients, hence confirming the appropriateness of surgical treatment for follicular and Hürthle cell neoplasia. Objective: To evaluate the diagnostic accuracy of systematic CT measurement in non-multiple endocrine neoplasia type 2 patients with nodular thyroid disease.
Settings: Study conducted at a national healthcare system hospital (outpatient and inpatient sectors).
Subjects: Consecutive patients with nodular thyroid disease (N = 5.817) were studied.
Main outcome measures:
Serum CT levels were measured under basal conditions. When basal CT values were more than or equal to 20 and less than 100 pg/ml, testing was repeated after pentagastrin stimulation. Basal or stimulated CT levels greater than 100 pg/ml were indication for surgery.
Results: Fifteen cases of MTC and seven of C-cell hyperplasia (CCH) were identified. MTCs were diagnosed in all patients with basal CT more than 100 pg/ml. The four patients with basal CT > 50 and < 100 pg/ml included two cases diagnosed with MTC and two cases with CCH. In ten patients with basal CT > 20 and < 50 pg/ml, histology confirmed the presence of MTC in four, four others had CCH, and the remaining two were negative for thyroid malignancy. Positive predictive values for basal CT levels in the preoperative diagnosis of MTC were: 23.1% for values > 20 pg/ml, 100% for values > 100 pg/ml, 25.0% for values > 50 and < 100 pg/ml, and 8.3% for values > 20 and < 50 pg/ml. Positive predictive values for the pentagastrin test (> 100 pg/ml) were 40% in the entire series.
Conclusions: CT screening of thyroid nodules is a highly sensitive test for early diagnosis of MTC, but confirmatory stimulation testing is necessary in most cases to identify true positive cases.
COMMENT
Medullary thyroid carcinomas (MTC) represent 4-10 % of all malignant thyroid neoplasms, and most of them (~75 %) are sporadic lesions. By the time patients with MTC present with clinical disease, the condition is usually already metastatic and the outcome poor. Thus, there is a good case for attempting to reach an early diagnosis, using CT measurement, in all patients with thyroid nodules. However, the systematic use of CT measurement in the initial work up (or follow up) of nodule patients remains controversial. The recent European thyroid cancer guidelines do advocate its use (see Europ. J. Endocrinol., 2006) while the equivalent U.S. guidelines do not (see Thyroid, 2006) . The prevalence of sporadic MTC in patients with thyroid nodules is low, in the order of 0.3-1.3 %. Does this low prevalence justify CT measurements in all nodular lesions? Plasma CT is a sensitive marker of CT-secreting C-cell disease and, therefore, routine determination of CT permits early diagnosis. The difficulty is that the real aim of screening nodules with CT measurement is not just the detection of smaller tumors (hence, indicating less advanced disease), but to reduce the overall morbidity and mortality of MTC, and this has unfortunately not yet been clearly demonstrated.
In the Editorial accompanying the article (by I. Borget et al.), the group of Martin Schlumberger discusses a medical economic rationale for the early detection of MTC, using CT measurement, and comes to the conclusion that "plasma CT determination in the assessment of thyroid nodule patients appears to be highly favourable compared with a number of other accepted healthy interventions". At the same time, these authors admit that further studies are obviously needed to confirm the benefits of routine CT screening and that, until then, uncertainties will remain and clinicians should use their own judgment, based on imperfect information. Methods: Forty-four consecutive patients, scheduled for hemithyroidectomy because of inconclusive FNAB results, participated in this prospective study.
18
F-FDG PET of the thyroid region was performed before surgery and standardized uptake values were calculated. The final histo-pathologic diagnosis served as a standard of reference.
Results: Histo-pathologic examination of the surgical specimen revealed 7 well-differentiated thyroid carcinomas in 6 patients, all accumulating 18 F-FDG (negative predictive value: 100%).
F-FDG accumulated in 13 of 38 benign nodules. The pre-PET probability for cancer in this study population was 14% (6/44), and the post-PET probability increased to 32% PET (6/19). The percentage of unnecessary hemithyroidectomies in a hypothetical algorithm using 18 F-FDG was only 30% (13/44), compared with 86% (38/44) without 18 F-FDG PET.
F-FDG PET reduced the number of futile hemithyroidectomies by 66% (25/38) (95% C.I.: 49%-80%; Fisher's exact test: P=0.0038). Semiquantitative analysis using standardized uptake values did not help to further reduce this number.
Conclusions:
In addition to data in the literature demonstrating accurate detection of thyroid cancer by 18 F-FDG PET, this study showed that 18 F-FDG PET should play an important role in the management of patients with inconclusive cytologic diagnosis of a thyroid nodule.
18
F-FDG PET reduced the number of futile hemithyroidectomies by 66%. Although PET is a relatively costly procedure, the cost outweighs the costs and risks associated with unnecessary thyroid surgery. 
COMMENT

